• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.满足社会对新型抗生素的需求：制药行业面临的挑战。
Br J Clin Pharmacol. 2015 Feb;79(2):168-72. doi: 10.1111/bcp.12401.
2
Antibiotic research and development: business as usual?抗生素研发：一切照旧？
J Antimicrob Chemother. 2015;70(6):1604-7. doi: 10.1093/jac/dkv020. Epub 2015 Feb 10.
3
Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.社会成本与通过专利延期立法刺激急需的抗生素研发所带来的节约对比。
Infection. 2007 Jun;35(3):167-74. doi: 10.1007/s15010-007-6269-7.
4
Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view.细菌病原体中的外排系统：治疗干预的契机？行业观点。
Biochem Pharmacol. 2006 Mar 30;71(7):949-56. doi: 10.1016/j.bcp.2005.10.021. Epub 2005 Nov 14.
5
Resistance to antibiotics: are we in the post-antibiotic era?抗生素耐药性：我们处于后抗生素时代吗？
Arch Med Res. 2005 Nov-Dec;36(6):697-705. doi: 10.1016/j.arcmed.2005.06.009.
6
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.新型抗菌药物临床开发面临的挑战与解决方案：制药行业专业人士的调查结果
Antimicrob Agents Chemother. 2015 Jul;59(7):3695-9. doi: 10.1128/AAC.00638-15. Epub 2015 Apr 27.
7
Alternative business models for drug discovery.药物研发的替代商业模式。
Drug Discov Today. 2011 Aug;16(15-16):643-5. doi: 10.1016/j.drudis.2011.06.012. Epub 2011 Jul 2.
8
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.应对抗生素耐药性：将新的财务激励措施与实现公共卫生目标相结合。
Health Aff (Millwood). 2010 Sep;29(9):1689-96. doi: 10.1377/hlthaff.2009.0439.
9
Decision making in the pharmaceutical industry - A tale of three antibiotics.制药行业的决策——三个抗生素的故事。
Int J Pharm. 2020 May 15;581:119251. doi: 10.1016/j.ijpharm.2020.119251. Epub 2020 Mar 21.
10
Beating bad bugs.战胜有害病菌。
Nat Rev Drug Discov. 2010 Sep;9(9):663. doi: 10.1038/nrd3265.

引用本文的文献

1
Evaluating the Potential and Synergetic Effects of Microcins against Multidrug-Resistant .评估微菌素对抗多重耐药菌的潜力和协同效应。
Microbiol Spectr. 2022 Jun 29;10(3):e0275221. doi: 10.1128/spectrum.02752-21. Epub 2022 May 11.
2
The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents.微生物毒素微菌素 B17：开发新型抗菌剂的前景。
J Mol Biol. 2019 Aug 23;431(18):3400-3426. doi: 10.1016/j.jmb.2019.05.050. Epub 2019 Jun 8.
3
The Effects of β-Lactam Antibiotics on Surface Modifications of Multidrug-Resistant Escherichia coli: A Multiscale Approach.β-内酰胺类抗生素对多重耐药性大肠杆菌表面修饰的影响：一种多尺度方法
Microsc Microanal. 2019 Feb;25(1):135-150. doi: 10.1017/S1431927618015696.
4
Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase.噻吩类抗菌药物通过变构作用稳定与 DNA 拓扑异构酶结合的 DNA 切割复合物。
Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4492-E4500. doi: 10.1073/pnas.1700721114. Epub 2017 May 15.
5
Benzofuran as a promising scaffold for the synthesis of antimicrobial and antibreast cancer agents: A review.苯并呋喃作为合成抗菌和抗乳腺癌药物的有前景骨架：综述
J Res Med Sci. 2015 Nov;20(11):1094-104. doi: 10.4103/1735-1995.172835.
6
Cooperative development of antimicrobials: looking back to look ahead.抗菌药物的合作开发：回顾与展望。
Nat Rev Microbiol. 2015 Oct;13(10):651-7. doi: 10.1038/nrmicro3523.
7
From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.从进化的角度来看，所有“新的”抗菌靶点其实都很古老：是时候跳出框框思考了。
Br J Clin Pharmacol. 2015 Feb;79(2):165-7. doi: 10.1111/bcp.12385.

本文引用的文献

1
Antibiotic resistance-the need for global solutions.抗生素耐药性——全球解决方案的必要性。
Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9. Epub 2013 Nov 17.
2
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.全球扩展型碳青霉烯酶肺炎克雷伯菌的临床流行病学。
Lancet Infect Dis. 2013 Sep;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7.
3
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.欧洲产碳青霉烯酶肠杆菌科细菌：39 个国家国家专家调查，2013 年 2 月。
Euro Surveill. 2013 Jul 11;18(28):20525. doi: 10.2807/1560-7917.es2013.18.28.20525.
4
Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.广泛耐药 VIM-2 阳性 ST235 铜绿假单胞菌在白俄罗斯、哈萨克斯坦和俄罗斯的传播：一项纵向流行病学和临床研究。
Lancet Infect Dis. 2013 Oct;13(10):867-76. doi: 10.1016/S1473-3099(13)70168-3. Epub 2013 Jul 9.
5
Platforms for antibiotic discovery.抗生素发现平台。
Nat Rev Drug Discov. 2013 May;12(5):371-87. doi: 10.1038/nrd3975.
6
Is the GAIN Act a turning point in new antibiotic discovery?GAIN 法案是否成为新抗生素发现的转折点？
Can J Microbiol. 2013 Mar;59(3):153-6. doi: 10.1139/cjm-2013-0089. Epub 2013 Feb 6.
7
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.制定全面的监管框架，以满足新抗菌治疗方法的未满足需求。
Lancet Infect Dis. 2013 Mar;13(3):269-75. doi: 10.1016/S1473-3099(12)70293-1. Epub 2013 Jan 15.
8
The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.时间贴现对克服抗生素市场失灵的经济激励的关键影响。
Nat Rev Drug Discov. 2012 Feb 1;11(2):168. doi: 10.1038/nrd3560-c1.
9
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.抗菌治疗的药代动力学-药效学：不再只是针对小鼠了。
Clin Infect Dis. 2007 Jan 1;44(1):79-86. doi: 10.1086/510079. Epub 2006 Nov 27.
10
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.药物研发环境中估算溶解度和渗透性的实验与计算方法。
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. doi: 10.1016/s0169-409x(00)00129-0.

满足社会对新型抗生素的需求：制药行业面临的挑战。

Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.

作者信息

O'Brien Seamus

机构信息

Infection Global Medicines Development, AstraZeneca, Macclesfield, Cheshire, UK.

出版信息

Br J Clin Pharmacol. 2015 Feb;79(2):168-72. doi: 10.1111/bcp.12401.

DOI:10.1111/bcp.12401
PMID:25601037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4309623/
Abstract

The rise of antibiotic resistance is leading to clinicians being increasingly faced with clinical failure due to the lack of effective and safe treatment options. New antibiotics are needed now for current multi-drug resistant infections but also in preparation for emerging and anticipated threats. There are significant challenges for the pharmaceutical industry to discover and develop new antibiotics including a business model that balances reasonable reimbursement with appropriate use. This summary reviews the key challenges and collaborative interventions that may contribute to addressing a societal problem.

摘要

抗生素耐药性的不断上升，导致临床医生越来越多地面临因缺乏有效且安全的治疗选择而出现的临床治疗失败情况。当下，不仅针对当前的多重耐药感染需要新的抗生素，而且为应对新出现的和预期的威胁也需要新抗生素。制药行业在发现和开发新抗生素方面面临重大挑战，包括要建立一种能在合理报销与合理使用之间取得平衡的商业模式。本综述探讨了可能有助于解决这一社会问题的关键挑战和合作干预措施。